BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Johnson and Johnson
Baxter
Federal Trade Commission
Merck
Chubb
US Army
Boehringer Ingelheim
Cipla

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019763

« Back to Dashboard

NDA 019763 describes IFEX/MESNEX KIT, which is a drug marketed by Baxter Hlthcare and is included in one NDA. It is available from one supplier. Additional details are available on the IFEX/MESNEX KIT profile page.

The generic ingredient in IFEX/MESNEX KIT is ifosfamide; mesna. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ifosfamide; mesna profile page.
Summary for 019763
Tradename:IFEX/MESNEX KIT
Applicant:Baxter Hlthcare
Ingredient:ifosfamide; mesna
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 019763
Mechanism of ActionAlkylating Activity
Suppliers and Packaging for NDA: 019763
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
IFEX ifosfamide INJECTABLE;INJECTION 019763 NDA Baxter Healthcare Corporation 0338-3991 0338-3991-01 1 VIAL, SINGLE-DOSE in 1 CARTON (0338-3991-01) > 20 mL in 1 VIAL, SINGLE-DOSE
IFEX ifosfamide INJECTABLE;INJECTION 019763 NDA Baxter Healthcare Corporation 0338-3993 0338-3993-01 1 VIAL, SINGLE-DOSE in 1 CARTON (0338-3993-01) > 60 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Dec 30, 1988TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength3GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Dec 30, 1988TE:APRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength1GM/VIAL;100MG/ML
Approval Date:Oct 10, 1992TE:RLD:No

Expired US Patents for NDA 019763

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare IFEX/MESNEX KIT ifosfamide; mesna INJECTABLE;INJECTION 019763-003 Oct 10, 1992 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-001 Dec 30, 1988 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX/MESNEX KIT ifosfamide; mesna INJECTABLE;INJECTION 019763-004 Oct 10, 1992 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-001 Dec 30, 1988 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX/MESNEX KIT ifosfamide; mesna INJECTABLE;INJECTION 019763-003 Oct 10, 1992 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-002 Dec 30, 1988 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-002 Dec 30, 1988 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX/MESNEX KIT ifosfamide; mesna INJECTABLE;INJECTION 019763-004 Oct 10, 1992 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX/MESNEX KIT ifosfamide; mesna INJECTABLE;INJECTION 019763-003 Oct 10, 1992 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX/MESNEX KIT ifosfamide; mesna INJECTABLE;INJECTION 019763-004 Oct 10, 1992 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Baxter
UBS
QuintilesIMS
Daiichi Sankyo
Deloitte
Johnson and Johnson
US Department of Justice
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot